ArticleScientific reports2026
Evaluation of prostate cancer diagnosis during the COVID-19 crisis in the French Caribbean.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer incidence varies considerably across regions worldwide. In Martinique, the incidence reached 164, 5 per 100,000 person-years between 2008 and 2014, ranking among the highest globally. During the COVID-19 pandemic, diagnostic activities were severely disrupted, which may have impacted prostate cancer outcomes. This study aimed to compare incidence, characteristics, and survival of prostate cancer patients diagnosed in Martinique before and during the COVID-19 pandemic. This study included patients diagnosed with invasive prostate adenocarcinoma between January 1, 2015, and December 31, 2022, from the Martinique Cancer Registry database. Patients were characterized according to the diagnosis period (pre-COVID vs. COVID). Variations in incidence were analysed using Poisson model. A log-rank test was used to compare survival curve. Multivariable Cox model were applied to identify factors for survival. A total of 4824 patients were included, with a mean age of 67.4 years (± 9.0). The incidence rate decreased by 18% after the onset of the pandemic (p = 0.006), followed by an average annual increase of 7% (p = 0.03). Overall survival was lower among patients diagnosed during the COVID-19 period (p = 0.007). The COVID-19 pandemic affected prostate cancer screening and diagnostic pathways as well as disease prognosis. Extended follow-up is required to assess the long-term impact on stage at diagnosis and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.